Extract

This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised, parallel group, fixed dose, for 12 weeks.

Inclusion criteria

• chronic kidney disease ,dialysis ,Hyperphosphatemia ,Dyslipidemia

Country

• Hungary
• Italy
• Macedonia, the former Yugoslav Republic of
• Malaysia
• Poland
• Russian Federation
• Serbia
• Ukraine

Links

• ictrp
• nct